Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer.
about
Persistent androgen receptor addiction in castration-resistant prostate cancerEmerging mechanisms of resistance to androgen receptor inhibitors in prostate cancerAdaptive responses of androgen receptor signaling in castration-resistant prostate cancerNovel Imidazopyridine Derivatives Possess Anti-Tumor Effect on Human Castration-Resistant Prostate Cancer CellsCombination of the PI3K inhibitor ZSTK474 with a PSMA-targeted immunotoxin accelerates apoptosis and regression of prostate cancerRegulation of the pentose phosphate pathway by an androgen receptor-mTOR-mediated mechanism and its role in prostate cancer cell growth.The Effects and Mechanism of YK-4-279 in Combination with Docetaxel on Prostate Cancer.Evaluation of ERG responsive proteome in prostate cancerThe role of mRNA splicing in prostate cancer.Inhibition of polo-like kinase 1 (Plk1) enhances the antineoplastic activity of metformin in prostate cancer.Elevated YKL40 is associated with advanced prostate cancer (PCa) and positively regulates invasion and migration of PCa cellsThe role of epithelial plasticity in prostate cancer dissemination and treatment resistanceMicroRNA profiling in prostate cancer--the diagnostic potential of urinary miR-205 and miR-214Transcription factor and microRNA-regulated network motifs for cancer and signal transduction networks.CD44 variant 6 is associated with prostate cancer metastasis and chemo-/radioresistance.Osteopontin-c mediates the upregulation of androgen responsive genes in LNCaP cells through PI3K/Akt and androgen receptor signaling.A genome-wide RNAi screen identifies FOXO4 as a metastasis-suppressor through counteracting PI3K/AKT signal pathway in prostate cancer.Nanomicellar TGX221 blocks xenograft tumor growth of prostate cancer in nude mice.Complex impacts of PI3K/AKT inhibitors to androgen receptor gene expression in prostate cancer cells.Prostate specific G protein coupled receptor is associated with prostate cancer prognosis and affects cancer cell proliferation and invasion.SATB1 Promotes Pancreatic Cancer Growth and Invasion Depending on MYC Activation.Resveratrol activates autophagic cell death in prostate cancer cells via downregulation of STIM1 and the mTOR pathwayTowards targeted combinatorial therapy design for the treatment of castration-resistant prostate cancer.EphA6 promotes angiogenesis and prostate cancer metastasis and is associated with human prostate cancer progression.Screening key microRNAs for castration-resistant prostate cancer based on miRNA/mRNA functional synergistic network.Cotargeting Androgen Receptor Splice Variants and mTOR Signaling Pathway for the Treatment of Castration-Resistant Prostate CancerEdelfosine Promotes Apoptosis in Androgen-Deprived Prostate Tumors by Increasing ATF3 and Inhibiting Androgen Receptor ActivityTargeting IκB Kinase β/NF-κB Signaling in Human Prostate Cancer by a Novel IκB Kinase β Inhibitor CmpdA.Hedgehog signaling in prostate cancer and its therapeutic implicationAssociation between Metformin Use and Cancer Stage at Diagnosis among Elderly Medicare Beneficiaries with Preexisting Type 2 Diabetes Mellitus and Incident Prostate Cancer.Understanding the temporal sequence of genetic events that lead to prostate cancer progression and metastasis.Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics.The PI3K-AKT-mTOR pathway activates recovery from general anesthesiaMiR-4638-5p inhibits castration resistance of prostate cancer through repressing Kidins220 expression and PI3K/AKT pathway activity.Non-Genomic Actions of the Androgen Receptor in Prostate CancerProstate cancer and the unfolded protein response.GABARAPL1 suppresses metastasis by counteracting PI3K/Akt pathway in prostate cancer.Neoadjuvant therapy for localized prostate cancer: Examining mechanism of action and efficacy within the tumor.PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance.Precision medicine for prostate cancer.
P2860
Q26777163-C15C42D3-E21B-490C-824B-B92564AFC5E9Q26777310-11CDFC55-1914-4709-B2B8-F475F2326477Q26795625-FBF45A6B-B94D-4BBF-B36D-4E2769A42039Q28545928-E0FCEEFA-B828-4399-9D1B-8B79D099E31DQ30557008-A9C9E30E-B1F7-44EA-A466-937A2BC4F17DQ33672445-31169E1B-EA62-425D-9FAE-9BD15B88B1C6Q33702987-F4F26C66-1C75-4CF1-AC00-8305F5F46F54Q33822319-E40D4B28-4A7F-43EF-B82B-C3D98124CCC9Q33922376-37731DF9-C068-4188-A830-96DF7B1819C5Q34042731-C846830B-70F9-43DA-A050-78C10A4A270DQ34052057-45340653-44A4-4615-BA97-43B9DC97E5EBQ34505037-D9C8FA4C-CDDF-495F-A0F7-9E01DB2DB517Q35027675-F4A1C5D8-7ADE-4EB3-91F8-2B229D737E9FQ35092844-DC67612C-2E81-465C-ADC0-1CA1726889CCQ35116847-CD14F214-164C-422C-B169-814851EFE710Q35167752-EF68BD45-5D81-4F4A-BCDD-EF7DE7829FF7Q35199286-0E83BF7C-89C6-4E47-B126-D42E99438BF7Q35224405-12B880EC-0849-4A89-9B89-978C2DE39CEDQ35382353-1B35CCAF-159A-4AFF-8F67-0F5F861B1048Q35845746-A7EFBB8C-3DEB-4024-B943-F2B308BEB881Q36210201-A91ED7CA-6BC5-40A4-9AF5-8EB523C0B137Q36218365-057579D8-543D-402B-A557-D470736C1B4DQ36329301-FD0DE9F2-821E-412F-9764-E9F57164DDA9Q36356025-2F3BDD7A-7118-47CE-A4BE-12A540BD8240Q36685517-CA5E9E0D-761E-489A-BECF-EB2613E388D7Q36963697-8FF920E4-1EFB-4A4B-994E-2DE672DD187BQ37066598-FC3F322A-54C1-4918-B3EA-DFAD37036F12Q37075277-125A46A2-2777-414D-B271-97E25F9D86C0Q37091887-3291FE6B-7040-4A2C-BD3B-DBD43C03FDD2Q37172118-C8C889B2-7CD8-4D1D-B300-5169B478F9E1Q37173154-13D2A65F-9CC4-41DA-BB14-53E4C1AF04ABQ37350230-983A0011-0E66-41F5-B7A6-E1F69C3C4939Q37520114-D24AC88A-07BA-45BB-9DD1-A4E67C5E1C7AQ37565167-704C7DF9-966D-4517-AD62-50C2DD52A65DQ37588620-55FD516F-C233-436E-80DA-96368291E831Q37619869-DACFBA08-2EC5-46A7-8F77-48D281F3CA2AQ37706206-682610BE-E9CB-492A-819B-7FA200199AE8Q38185175-F073A80F-242C-4F2E-81C8-2925C8CEFFC1Q38206682-42B64AC1-AF81-4F32-89CA-75468A7CCBFEQ38263711-F2A2F845-E780-4E1E-B0C8-55B305AC5F5C
P2860
Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer.
@en
type
label
Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer.
@en
prefLabel
Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer.
@en
P356
P1476
Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer.
@en
P2093
Andrew J Armstrong
Rhonda L Bitting
P304
P356
10.1530/ERC-12-0394
P577
2013-05-20T00:00:00Z